Interrogating the impact of combination antiretroviral therapies on HIV‐associated neurocognitive disorders
Author:
Open Access
- 21 July 2021
- journal article
- review article
- Published by Wiley in HIV Medicine
- Vol. 22 (9) , 783-790
Abstract
Objectives: Although the advent of Combination Antiretroviral Therapy (cART) has greatly reduced the prevalence of HIV‐Associated Dementia, the most severe form of HIV‐Associated Neurocognitive Disorder (HAND), the incidence of the milder forms of HAND have risen. The explanations proposed include persistent central nervous system (CNS) viraemia and the neurotoxicity of chronic cART regimens. Nonetheless, controversies in HAND prevalence estimates, alongside a lack of consensus on the significance of CNS Penetration Effectiveness (CPE) have added to the complexity of elucidating the role of cART in HAND. The present review will evaluate the evidence underlying these explanations, as well as highlighting the need for improved trial designs and the incorporation of emerging biomarkers and neuroimaging tools.Methods: A review of the current literature investigating cART neurotoxicity, controversies in HAND prevalence estimates, CNS Penetration Effectiveness, and neuroprotective adjuvant therapies.Conclusions: Ultimately, the inadequacy of cART in achieving complete preservation of the CNS underscores the imminent need for neuroprotective adjuvant therapies, where the efficacy of combining multiple adjuvant classes presents a potential therapeutic frontier which must be interrogated.Keywords
This publication has 49 references indexed in Scilit:
- The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in AstrocytesPLOS ONE, 2013
- The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?BMC Infectious Diseases, 2011
- Minocycline treatment for HIV-associated cognitive impairmentNeurology, 2011
- HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsJournal of NeuroVirology, 2010
- HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral TreatmentThe Journal of Infectious Diseases, 2010
- HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapyNeurology, 2010
- Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohortNeurology, 2010
- Resting cerebral blood flowNeurology, 2009
- Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapyNeurology, 2009
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceAIDS, 2009